somatostatin receptor

2-Aminoethanethiol (Cysteamine) is a Cystine Depleting Agent. The mechanism of action of cysteamine is as a Cystine Disulfide Reduction.

Cyclosomatostatin Acetate is an effective antagonist of the somatostatin receptor.Cyclosomatostatin Acetate inhibits SSTR1 signaling and decreases cell proliferation, ALDH+ cell population size, and sphere-formation in colorectal cancer cells.

Octreotide (SMS 201-995) is a potent inhibitor of growth hormone, glucagon, and insulin.

L-796,778 acetate is a slective somatostatin receptor agonist with IC50 of 24nM for sst3, for sst1, sst2, sst4 and sst5, IC50 is >1000nM.

Octreotide Acetate (Sandostatin) is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone.

Paltusotine is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability. Paltusotine maintains GH and IGF-1 levels in acromegaly patients

Cortistatin 14, human, rat acetate is a neuropeptide having structural similarity to somatostatin-14 and shows anticonvulsive, neuroprotective effects and remarkable anti-inflammatory properties. Cortistatin 14, human, rat acetate binds and exerts its fun

CYN 154806 TFA is a cyclic octapeptide and an effective selective somatostatin sst2 receptor antagonist. For the recombinant sst2, sst1, sst3, sst4 and sst5 receptors, the pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48, respectively.

Cortistatin-14 acetate, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 acetate shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

L-797,591 hydrochloride is active for somatostatin receptor isoform 1 (SSTR1). L-797,591 hydrochloride is commonly used in combination with AG1478 to enhance p-ERK5 expression in SSTR1 cells. L-797,591 hydrochloride significantly enhanced p38 phosphorylation in cotransfected cells, and this effect was reversed in combination with AG1478.

The ED50 of J-2156 in rats for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws was 3.7 and 8.0 mg/kg, respectively. J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC5

SSTR5 antagonist 1 is a selective, and orally available antagonist of somatostatin receptor subtype 5 (SSTR5)(IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively).

SSTR5 antagonist 2 is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5),with potential to treat type 2 diabetes mellitus (T2DM).

SSTR5 antagonist 2 TFA is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5), with potential to treat type 2 diabetes mellitus (T2DM).

Vapreotide diacetate is a synthetic analog of somatostatin. It has analgesic activity most likely mediated through the blockade of the neurokinin-1 receptor (NK1R), the substance P (SP)-preferring receptor.

Pentetreotide is an indium-labeled somatostatin analog and can be used for nuclear medicine imaging. Pentetreotide is a diethylenetriaminopentaacetic conjugate of Octreotide. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizin

Branosotine (compound 1-1) acts as a potent agonist for the somatostatin receptor (SSTR2), exhibiting an EC50 of less than 0.1 nM.

SSTR4agonist-1 (Compound 47) is a selective agonist of the somatostatin receptor 4 (SSTR4), with an EC50 of 4.7 nM. It has a half-life of over 130 minutes in human liver microsomes.

MMC(TMZ)-TOC TFA exhibits high binding affinity and selectivity for the somatostatin receptor subtype 2 (SSTR2). It targets the delivery of TMZ to SSTR2-positive tumor cells, making MMC(TMZ)-TOC TFA useful for cancer research.

SSTR4 agonist5 (Compound 5) is an orally active agonist of the somatostatin receptor 4 (SSTR4) with an EC50 of 0.228 nM. It demonstrates good stability in human/rat liver microsomes and can inhibit mechanical hyperalgesia in rat models.

MMC(TMZ)-TOC exhibits a high binding affinity and selectivity for somatostatin receptor subtype 2 (SSTR2). It is designed to target and deliver TMZ specifically to SSTR2-positive tumor cells. MMC(TMZ)-TOC is applicable for cancer research.

SST1 receptor antagonist-1 (Compound 23) is a selective antagonist of the somatostatin receptor 1 (SST1), showing a pKd of 9.11 for rSST1 and 8.79 for hSST1. This compound is applicable in research related to retinal and endocrine dysfunction, cancer, and neuropsychiatric disorders.

SST1 receptor antagonist-2 (Example 2) is a piperazine derivative and an antagonist of the somatostatin receptor 1 (SST1). It can be utilized in research on psychiatric disorders, neurodegenerative diseases, tumors, vascular disorders, and immune diseases.